The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Clinicians typically first turn to antiarrhythmic drugs, but switching up the order may be offer patients better outcomes.

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

CHICAGO, IL—Giving rivaroxaban (Xarelto; Bayer/Janssen) to adults under the age of 65, after an atrial fibrillation (AF) ...

CHICAGO, IL—The weight-loss medication tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and ...

Total and LDL cholesterol variability over time may be a biomarker for higher dementia risk and cognitive decline.

COVID-19 “magnified” preexisting disparities for rural patients as compared with their urban counterparts, one study author ...

Ami Bhatt asks Kate Dalton to share details on the challenges of early feasibility studies from her perspective as a clinical site coordinator.

Ami Bhatt and Michael Mack explain the economics of AI use in the detection of subclinical cardiovascular disease.

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

The latest version of the LLM had high concordance with a multidisciplinary heart team in choosing between PCI and CABG.

In high- and standard-risk patients CAS and TCAR look good, but some worry about skill sets, learning curves, and ...